Internal Medicine, Nephrology · Altoona, PA
NPI
1932480571
Since 2011
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
312 Chestnut Avenue
Altoona, PA, 16601
Phone (814) 946-3500
Groups this clinician bills Medicare through
Medicare paid, 2024
$113K
1,477 services
Medicare patients, 2024
232
Average age 74
Drug cost, 2024
$405K
3,334 prescriptions
Company payments, 2025
$645
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Duminda S Siripala was code 99231 (hospital e&m - subsequent), 376 times for 82 patients. In total Duminda S Siripala billed 1,477 services in 16 codes, and Medicare paid $113K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99231 Hospital E&M - Subsequent | Facility | 376 | 82 | $39.69 | $15K |
| 99214 Office E&M - Established | Office | 166 | 113 | $76.92 | $13K |
| 90935 Hemodialysis | Facility | 162 | 34 | $56.69 | $9,183 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 152 | 110 | $13.33 | $2,026 |
| 90960 ESRD Related Services (not dialysis) | Office | 145 | 21 | $279.65 | $41K |
| 99222 Hospital E&M - Initial | Facility | 100 | 79 | $102.99 | $10K |
| 90961 ESRD Related Services (not dialysis) | Office | 62 | 23 | $226.75 | $14K |
| 99204 Office E&M - New | Office | 24 | 24 | $135.66 | $3,256 |
| 99213 Office E&M - Established | Office | 21 | 21 | $66.61 | $1,399 |
By year: 2022 $118K for 1,794 services; 2023 $85K for 1,444 services; 2024 $113K for 1,477 services.
Medicare prescription drug claims, 2024
In 2024, the drug Duminda S Siripala prescribed most often to Medicare patients was Calcitriol, with 550 prescriptions and refills. In total Duminda S Siripala wrote 3,334 Medicare prescriptions that cost $405K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calcitriol Generic | 550 | 764 | 107 | $8,444 |
| Losartan Potassium Generic | 345 | 518 | 79 | $2,875 |
| Prosol Parenteral Amino Acid 20% No.1 | 243 | 243 | Under 11 | $39K |
| Lisinopril Generic | 169 | 318 | 48 | $1,135 |
| Farxiga Dapagliflozin Propanediol | 115 | 130 | 26 | $71K |
| Amlodipine Besylate Generic | 105 | 162 | 25 | $544 |
| Furosemide Generic | 101 | 129 | 28 | $376 |
| Bumetanide Generic | 100 | 100 | 16 | $4,201 |
| Sevelamer Carbonate Generic | 91 | 119 | 27 | $6,256 |
| Jardiance Empagliflozin | 88 | 102 | 15 | $58K |
| Spironolactone Generic | 78 | 90 | 15 | $501 |
| Tamsulosin Hcl Generic | 66 | 120 | 18 | $636 |
| Hydrochlorothiazide Generic | 66 | 76 | 14 | $153 |
| Calcium Acetate Generic | 60 | 87 | 17 | $3,894 |
| Potassium Chloride Generic | 54 | 66 | 19 | $729 |
Brand drugs: 711 claims; generic drugs: 2,623 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Duminda S Siripala $645 ($645 in general payments such as food, travel and fees) from 14 companies. The largest payer was Otsuka America Pharmaceutical, Inc. with $159.
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. 4578.T | 9 | $159 |
| GlaxoSmithKline, LLC. GSK | 1 | $126 |
| Amgen Inc. AMGN | 3 | $57.76 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $52.88 |
| Novo Nordisk Inc NVO | 2 | $41.64 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $27.89 |
| Alnylam Pharmaceuticals Inc. ALNY | 1 | $26.57 |
| Kyowa Kirin, Inc. 4151.T | 1 | $24.58 |
| Akebia Therapeutics Inc AKBA | 1 | $24.47 |
| Mallinckrodt Hospital Products Inc. | 1 | $23.84 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.